Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients

Clinical Cancer Research

Volumn 18, Issue 19, 2012, Pages 5460-5470

  Aarntzen, Erik H J G ^a,b   Schreibelt, Gerty ^a   Bol, Kalijn ^a,b   Lesterhuis, W Joost ^b   Croockewit, Alexandra J ^b   De Wilt, Johannes H W ^b   Van Rossum, Michelle M ^b   Blokx, Willeke A M ^b   Jacobs, Joannes F M ^b   Duiveman De Boer, Tjitske ^a   Schuurhuis, Danita H ^a   Mus, Roel ^b   Thielemans, Kris ^c   De Vries, I Jolanda M ^a,b   Figdor, Carl G ^a   Punt, Cornelis J A ^d   Adema, Gosse J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GLYCOPROTEIN GP 100; HLA ANTIGEN; KEYHOLE LIMPET HEMOCYANIN; MESSENGER RNA; MONOPHENOL MONOOXYGENASE; SELUMETINIB; TEMOZOLOMIDE; TUMOR ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BLOOD ANALYSIS; CANCER PATIENT; CANCER STAGING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUTANEOUS MELANOMA; CYTOKINE PRODUCTION; DISTANT METASTASIS; ELECTROPORATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHOCYTE COUNT; MALE; MELANOMA; MONOCYTE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SKIN TEST; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; ELECTROPORATION; FEMALE; GP100 MELANOMA ANTIGEN; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; MALE; MELANOMA; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; NEOPLASM METASTASIS; NEOPLASM STAGING; RNA, MESSENGER;

EID: 84866945151     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-3368     Document Type: Article

References (45)

1. Lesterhuis WJ, Aarntzen EHJG, Vries IJM, Schuurhuis DH, Figdor CG, Adema GJ, et al. Dendritic cell vaccines in melanoma: from promise to proof? Crit Rev Oncol Hematol 2008;66:118-34.
2. Lesterhuis WJ, de Vries IJ, Schreibelt G, Lambeck AJ, Aarntzen EH, Jacobs JF, et al. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res 2011;17:5725-35.
3. Schultz ES, Schuler-Thurner B, Stroobant V, Jenne L, Berger TG, Thielemanns K, et al. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy. J Immunol 2004;172:1304-10. (Pubitemid 38113794)
4. Verdijk P, Aarntzen EHJG, Lesterhuis WJ, Boullart ACI, Kok E, van Rossum MM, et al. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res 2009;15:2531-40.
5. Wilgenhof S, Van Nuffel AM, Corthals J, Heirman C, Tuyaerts S, Benteyn D, et al. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J Immunother 2011;34:448-56.
6. Laverman P, de Vries IJM, Scharenborg NM, de Boer A, Broekema M, Oyen WJG, et al. Development of In-111-labeled tumor-associated antigen peptides for monitoring dendritic-cell-based vaccination. Nucl Med Biol 2006;33:453-8. (Pubitemid 43729854)
7. Mitchell DA, Nair SK. RNA-transfected dendritic cells in cancer immunotherapy. J Clin Invest 2000;106:1065-9.
8. Skipper JCA, Hendrickson RC, Gulden PH, Brichard V, Vanpel A, Chen Y, et al. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 1996;183:527-34. (Pubitemid 26059516)
9. Zarling AL, Ficarro SB, White FM, Shabanowitz J, Hunt DF, Engelhard VH. Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo. J Exp Med 2000;192:1755-62. (Pubitemid 32049768)
10. Schuurhuis DH, Verdijk P, Schreibelt G, Aarntzen EHJG, Scharenborg NM, de Boer A, et al. In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients. Cancer Res 2009;69:2927-34.
11. Van Tendeloo V, Ponsaerts P, Lardon F, Nijs G, Lenjou M, Van Broeckhoven C, et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 2001;98:49-56.
12. Schuurhuis DH, Lesterhuis WJ, Kramer M, LoomanMGM, Hout-Kuijer M, Schreibelt G, et al. Polyinosinic polycytidylic acid prevents efficient antigen expression after mRNA electroporation of clinical grade dendritic cells. Cancer Immunol Immunother 2009;58:1109-15.
13. Gajewski TF, Meng Y, Harlin H. Immune suppression in the tumor microenvironment. J Immunother 2006;29:233-40. (Pubitemid 44297291)
14. Gajewski TF. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 2007;13(18 Pt 1):5256-61. (Pubitemid 47510348)
15. Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 2006;213:131-45. (Pubitemid 44401498)
16. Eggermont AM, Testori A, Marsden J, Hersey P, Quirt I, Petrella T, et al. Utility of adjuvant systemic therapy in melanoma. Ann Oncol 2009;20(Suppl 6):vi30-4.
17. de Vries IJM, Lesterhuis WJ, Scharenborg NM, Engelen LPH, Ruiter DJ, Gerritsen MJP, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 2003;9:5091-100. (Pubitemid 37413557)
18. Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, et al. Proinflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under FCS-free conditions. Effect of culture conditions on the type of T cell response. Eur J Immunol 1997;27:3135-42. (Pubitemid 28018007)
19. de Vries IJM, Eggert AAO, Scharenborg NM, Vissers JLM, Lesterhuis WJ, Boerman OC, et al. Phenotypical and functional characterization of clinical grade dendritic cells. J Immunother 2002;25:429-38.
20. Figdor CG, de Vries IJM, Lesterhuis WJ, Melief CJM. Dendritic cell immunotherapy: mapping the way. Nat Med 2004;10:475-80. (Pubitemid 38667904)
21. de Vries IJM, Bernsen MR, Lesterhuis WJ, Scharenborg NM, Strijk SP, Gerritsen MJP, et al. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 2005;23:5779-87.
22. Morse MA, Lyerly HK. Clinical applications of dendritic cell vaccines. Curr Opin Mol Ther 2000;2:20-8. (Pubitemid 30140201)
23. Germeau C, MaWB, Schiavetti F, Lurquin C, Henry E, Vigneron N, et al. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 2005;201:241-8.
24. Kyte JA, Mu L, Aamdal S, Kvalheim G, Dueland S, Hauser M, et al. Phase I/II trial of melanoma therapy with dendritic cells transfectedwith autologous tumor-mRNA. Cancer Gene Ther 2006;13:905-18. (Pubitemid 44373791)
25. Hugues S, Fetler L, Bonifaz L, Helft J, Amblard F, Amigorena S. Distinct T cell dynamics in lymph nodes during the induction of tolerance and immunity. Nat Immunol 2004;5:1235-42. (Pubitemid 41057738)
26. Iezzi G, Karjalainen K, Lanzavecchia A. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity 1998;8:89-95. (Pubitemid 28097826)
27. Bonehill A, Tuyaerts S, Van Nuffel AM, Heirman C, Bos TJ, Fostier K, et al. Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther 2008;16:1170-80. (Pubitemid 351737084)
28. Keene JA, Forman J. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J Exp Med 1982;155:768-82. (Pubitemid 12187851)
29. + T cells in the priming and effector/memory phases of adoptive immunotherapy. J Immunol 2000;165:4246-53.
30. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJM. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998;187:693-702. (Pubitemid 28115185)
31. Toes REM, Ossendorp F, Offringa R, Melief CJM. CD4 T cells and their role in antitumor immune responses. J Exp Med 1999;189:753-6. (Pubitemid 29189679)
32. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998;393:480-3.
33. + T cells support cytotoxic T lymphocyte priming by controlling lymph node input. Proc Natl Acad Sci U S A 2011;108:8749-54.
34. + T lymphocytes. Cancer Res 2010;70:8368-77.
35. Marzo AL, Kinnear BF, Lake RA, Frelinger JJ, Collins EJ, Robinson BWS, et al. Tumor-specific CD4(+) T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J Immunol 2000;165:6047-55.
36. + T cells. J Immunol 2008;180:3122-31.
37. + T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J Immunol 2000;164:3902-12.
38. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001;106:255-8. (Pubitemid 32772607)
39. + T lymphocytes against human melanoma. Evidence for a shared melanoma antigen presented by HLA-DR15. J Immunol 1995;154:772-9.
40. Campillo JA, Martinez-Escribano JA, Muro M, Moya-Quiles R, Marin LA, Montes-Ares O, et al. HLA class I and class II frequencies in patients with cutaneous malignant melanoma from southeastern Spain: the role of HLA-C in disease prognosis. Immunogenetics 2006;57:926-33. (Pubitemid 43185427)
41. Rodriguez T, Mendez R, Del CA, Aptsiauri N, Martin J, Orozco G, et al. Patterns of constitutive and IFN-gamma inducible expression of HLA class II molecules in human melanoma cell lines. Immunogenetics 2007;59:123-33. (Pubitemid 46130791)
42. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
43. Robert C, Thomas L, Bondarenko I, O'Day S, JW MD, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
44. Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010;102:1388-97.
45. Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy-revisited. Nat Rev Drug Discov 2011;10:591-600.